MoonLake Immunotherapeutics (MLTX)
| Market Cap | 862.98M +32.5% |
| Revenue (ttm) | n/a |
| Net Income | -263.67M |
| EPS | -3.81 |
| Shares Out | 85.11M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,772,739 |
| Open | 10.30 |
| Previous Close | 10.41 |
| Day's Range | 10.01 - 10.65 |
| 52-Week Range | 8.80 - 23.29 |
| Beta | 1.08 |
| Analysts | Buy |
| Price Target | 28.54 (+181.46%) |
| Est. Earnings | Nov 4, 2026 |
About MLTX
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
Financial Performance
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for MLTX stock is "Buy." The 12-month stock price target is $28.54, which is an increase of 181.46% from the latest price.
News
MoonLake price target raised to $50 from $45 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $50 from $45 and keeps a Buy rating on the shares. The company reported positive results from the…
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial
MoonLake Immunotherapeutics said on Monday its experimental drug met all main goals in a late-stage trial involving adults with an inflammatory disease who had not previously received biologic medic...
MoonLake Immunotherapeutics reports Q2 EPS (84c), consensus (90c)
MoonLake held cash, cash equivalents and short-term marketable debt securities of $537M. The company expects to have sufficient capital to fund its operating expenses and capital expenditure requireme...
MoonLake says Phase 3 IZAR-1 trial met all clinical endpoints at Week 16
MoonLake Immunotherapeutics (MLTX) announced positive topline results from the Phase 3 IZAR-1 trial evaluating sonelokimab in biologic-naive adults with active psoriatic arthritis. The IZAR Phase 3 pr...
MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results
Phase 3 IZAR-1 trial in bio-naïve patients met all clinical endpoints at Week 16 for 60 mg sonelokimab The primary endpoint of ACR50 was met with a high response of 42.1% for sonelokimab's 60 mg with ...
MoonLake Immunotherapeutics Earnings release: Q2 2026
MoonLake Immunotherapeutics released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
MoonLake Immunotherapeutics Quarterly report: Q2 2026
MoonLake Immunotherapeutics has published its Q2 2026 quarterly earnings report on August 10, 2026.
MoonLake Immunotherapeutics 9M share Secondary priced at $20.00
The deal size was increased to $200M in common stock and prefunded warrants from $150M. Leerink, Guggenheim, Cantor Fitzgerald and LifeSci Capital acted as joint book running managers for the…
MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering
ZUG, Switzerland, June 23, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joi...
MoonLake Immunotherapeutics announces $150M offering of Class A ordinary shares
MoonLake Immunotherapeutics (MLTX) announced a proposed public offering of $150M of its Class A ordinary shares and, in lieu of Class A ordinary shares to certain investors that so choose,…
MoonLake Immunotherapeutics Announces Proposed Public Offering
ZUG, Switzerland, June 22, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joi...
MoonLake’s SLK has ‘blockbuster potential,’ says Clear Street
Following MoonLake Immunotherapeutics (MLTX)’ investor event focused on the development and commercialization of SLK in hidradenitis suppurativa, Clear Street views SLK’s HS profile as “highly competi...
MoonLake Immunotherapeutics Transcript: Investor Day 2026
Sonelokimab's phase III data in HS show leading efficacy, safety, and convenience, supporting a broad label and BLA submission by end of Q3. Commercial preparations are advanced for a large, underpenetrated market, with strong prescriber and stakeholder enthusiasm. Priority review and pediatric labeling are possible.
MoonLake Immunotherapeutics Slides: FY 2026
MoonLake Immunotherapeutics has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 22, 2026.
MoonLake announces Week 52 results of Phase 3 VELA-1, VELA-2 trials
MoonLake Immunotherapeutics (MLTX) announced the Week 52 results of the Phase 3 VELA-1 and VELA-2 clinical trials of its registrational global program in patients with moderate-to-severe HS. The Compa...
MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026
ZUG, Switzerland, June 21, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (MoonLake or the Company), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory...
MoonLake Immunotherapeutics Earnings release: Q1 2026
MoonLake Immunotherapeutics released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
MoonLake Immunotherapeutics Quarterly report: Q1 2026
MoonLake Immunotherapeutics has published its Q1 2026 quarterly earnings report on May 11, 2026.
MoonLake price target raised to $45 from $40 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on MoonLake Immunotherapeutics (MLTX) to $45 from $40 and keeps a Buy rating on the shares. The company announced a positive outcome of…
MoonLake FDA meeting yields ‘best-in-class’ label, says Clear Street
Clear Street says MoonLake Immunotherapeutics’s (MLTX) positive pre-application meeting with the restores to its “prior strong positioning” in the hidradenitis suppurativa competitive landscape. The F...
MoonLake says aligned with FDA on submission plans for sonelokimab
MoonLake Immunotherapeutics (MLTX) announced a “positive” outcome of its final pre-BLA meeting held on April 1 with the FDA on the HS program of its Nanobody SLK. “During the meeting,…
MoonLake Immunotherapeutics reports Q1 EPS -98c vs. -91c last year
MoonLake reported its financial results for the first quarter of 2026. As of March 31, 2026, MoonLake held cash, cash equivalents and short-term marketable debt securities of $357.9M. The company…
MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results
ZUG, Switzerland, May 10, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake” or the “Company”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammat...
MoonLake Immunotherapeutics Proxy statement: Proxy filing
MoonLake Immunotherapeutics filed a proxy statement on April 21, 2026, providing details for shareholder voting and corporate governance matters.
MoonLake Immunotherapeutics Proxy statement: Proxy filing
MoonLake Immunotherapeutics filed a proxy statement on April 21, 2026, providing details for shareholder voting and corporate governance matters.